AU2003283339A1 - Cancer therapy determination - Google Patents

Cancer therapy determination

Info

Publication number
AU2003283339A1
AU2003283339A1 AU2003283339A AU2003283339A AU2003283339A1 AU 2003283339 A1 AU2003283339 A1 AU 2003283339A1 AU 2003283339 A AU2003283339 A AU 2003283339A AU 2003283339 A AU2003283339 A AU 2003283339A AU 2003283339 A1 AU2003283339 A1 AU 2003283339A1
Authority
AU
Australia
Prior art keywords
cancer therapy
therapy determination
determination
cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003283339A
Inventor
Paul Harkin
Richard Kennedy
Jennifer Quinn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Publication of AU2003283339A1 publication Critical patent/AU2003283339A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AU2003283339A 2002-11-05 2003-11-03 Cancer therapy determination Abandoned AU2003283339A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0226595.7 2002-11-05
GBGB0226595.7A GB0226595D0 (en) 2002-11-15 2002-11-15 Cancer therapy determination
PCT/EP2003/012245 WO2004042080A1 (en) 2002-11-05 2003-11-03 Cancer therapy determination

Publications (1)

Publication Number Publication Date
AU2003283339A1 true AU2003283339A1 (en) 2004-06-07

Family

ID=9947830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003283339A Abandoned AU2003283339A1 (en) 2002-11-05 2003-11-03 Cancer therapy determination

Country Status (3)

Country Link
AU (1) AU2003283339A1 (en)
GB (1) GB0226595D0 (en)
WO (1) WO2004042080A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL217731B1 (en) * 2006-06-01 2014-08-29 Tomasz Byrski Detection of lowered response for chemotherapy with the use of cytostatics from a group of toxoids
PL212012B1 (en) * 2008-07-06 2012-07-31 Tomasz Byrski Detection of existence of increased risk of chemotherapy side effects by the use of platinum cytostatics
WO2010037224A1 (en) * 2008-10-03 2010-04-08 St. Michael's Hospital Method for preventing and treating cardiovascular diseases with brca1
ES2704303T3 (en) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedures for the prediction of a response against cancer
CA3080441A1 (en) * 2012-02-23 2013-09-06 The Children's Hospital Corporation Methods for predicting anti-cancer response
GB2553736A (en) * 2015-05-19 2018-03-14 S Sridhar T Method for identification of a deficient BRCA1 function

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473642A1 (en) * 2002-01-25 2003-08-07 Sheikh Ismail Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy

Also Published As

Publication number Publication date
WO2004042080A1 (en) 2004-05-21
GB0226595D0 (en) 2002-12-24

Similar Documents

Publication Publication Date Title
AUPS054702A0 (en) Cancer therapy
AU2003201741A1 (en) Cancer profiles
AU2003224654A1 (en) Photodynamic therapy for pre-melanomas
AU2003235470A1 (en) Predictive markers in cancer therapy
AU2003224076A1 (en) Antibody combination useful for tumor therapy
AU2002226650A1 (en) Redox therapy for tumors
AU2003212634A1 (en) Compounds useful in the treatment of cancer
EP2561887B8 (en) Cancer therapy sensitizer
EP1594433A3 (en) Cancer therapy sensitizer
AU2003247005A1 (en) Therapy combination
AU2003245794A1 (en) Glycosaminoglycan-dnase combination therapy
AU2003289603A1 (en) Tumor vaccine
AU2003223538A1 (en) Methods for the treatment of cancer
AU2003222449A1 (en) Medicine for treating cancer
AU2003215150A1 (en) Therapeutic compounds
AU2002335667A1 (en) Modified reoviral therapy
AU2003283339A1 (en) Cancer therapy determination
AU2003212826A1 (en) Cancer genes
AU2003231803A1 (en) Treatment of cancer with mefloquire
AU2003302625A1 (en) Silicon compounds useful in cancer therapy
AU2003285079A1 (en) Neurostimulation therapy manipulation
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
AU2002351382A1 (en) Combination cancer therapy
AU2003223317A1 (en) Determining cancer aggressiveness
AU2003231937A1 (en) Therapeutic methods

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase